10-OR: Implementing CGM with a Family Behavioral Intervention (FBI) Reduces Psychosocial Distress in Parents of Children 2-8 Y/O: A Pre–Post Comparison

Abstract

Parents of young children with T1D face daily psychosocial stressors that may be mitigated or worsened by the use of diabetes technologies. We assessed psychosocial functioning in parents before and after beginning CGM supported by a FBI in youth 2-<8 y/o in the Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study. SENCE had three treatment arms: CGM + FBI, CGM alone, and standard BG monitoring (BGM). We analyzed data from 44 children in the BGM group (47% male, 63% non-Hispanic white, age 6.7±1.8 yrs, T1D duration 3.2±2.0 yrs; 43% pump-treated, A1c 8.1±0.8%) who initiated CGM (Dexcom G5™) with FBI (behavioral support of CGM use) after 6 months. Parents completed validated measures of diabetes family impact (DFIS), technology satisfaction (DTQ), fear of hypoglycemia (FOH), and diabetes distress (PAID) at 6 (CGM start) and 12 months. Longitudinal models assessed change in psychosocial functioning. After 6 months of CGM use, parents reported greater technology satisfaction, reduced FOH (total and worry), and decreased diabetes distress (all p≤0.003), with a trend towards reduced family impact (p=0.06) (Figure). Implementing CGM in young children within the context of a tailored FBI intervention was associated with improved psychosocial outcomes for parents, reaffirming primary results of the SENCE Study and benefits of supported technology use. Disclosure P.V. Commissariat: None. L. Kanapka: None. K. Miller: None. M.E. Hilliard: None. B. Anderson: None. L. DiMeglio: None. L.M. Laffel: Advisory Panel; Self; Roche Diabetes Care. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., ConvaTec Inc., Dexcom, Inc., Insulet Corporation, Insulogic LLC, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc., Sanofi US. Funding The Leona M. and Harry B. Helmsley Charitable Trust